Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD
Liver International · 2026-04 · 46 (4)
DOI: 10.1111/liv.70562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 23.02.2026. Verfasst von Alex E Henney und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Hormone Replacement Therapy, Fatty Liver, Estrogen Replacement Therapy, Metabolic Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction, contributing to heightened risk of progressive liver and cardiovascular disease. Hormone replacement therapy (HRT), supported by pre‐clinical data, may be associated with a lower risk.
Methods
We performed a retrospective cohort study using the TriNetX global federated research network. Eligible participants were peri‐menopausal women (ICD‐10 codes N95/Z78.0, AND age 40–65 years) with pre‐existing MASLD (based on ICD‐10 codes K76.0/K75.81 or positive modified hepatic steatosis index plus ≥ 1 metabolic syndrome, MetS, trait). Patients initiating HRT (oestrogen ± progesterone) were compared with untreated controls using 1:1 propensity score matching for demographics, comorbidities, biochemistry and medications. The primary outcome was a composite of major adverse liver outcomes (MALO: portal hypertension, varices, ascites, spontaneous bacterial peritonitis, encephalopathy, hepatorenal/pulmonary syndromes, cirrhosis, decompensated liver disease, hepatocellular carcinoma, liver transplant). Secondary outcomes were individual MALO components, type 2 diabetes (T2D), major adverse cardiovascular events (MACE), breast and endometrial cancer, and venous thromboembolism (VTE). Cox regression generated hazard ratios (HRs) with 95% CIs over 5 years. Sensitivity analyses adjusted for geography, hormone type, and degree of obesity.
Results
After matching, 21 639 patients were included in each treatment arm. HRT was associated with a significantly reduced risk of MALO (HR 0.80; 0.71, 0.9), largely driven by reductions in ascites and SBP (0.78; 0.64, 0.95), and liver cirrhosis (0.75; 0.63, 0.90), and reduced risk of cardiometabolic outcomes: T2D (0.90; 0.84, 0.96), and MACE (0.90; 0.83, 0.98). HRT was not associated with increased risk of breast cancer or VTE, whilst endometrial cancer risk was reduced (0.49; 0.40, 0.61). Oestrogen was linked to greater benefits compared to progesterone, and patients with mild–moderate obesity experienced more significant risk reduction.
Conclusion
Treatment of peri‐menopausal symptoms with HRT, in patients with pre‐existing MASLD, is associated with a lower 5‐year risk of major liver and cardiometabolic disease. These findings support early basic science research and should prompt a closer examination through clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
- Metabolism and Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
- Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
- Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
ORCID-Profile: Alex E Henney, Daniel J Cuthbertson
Zitieren
APA
Henney, A. E., Wilson, J., Riley, D. R., Alam, U., & Cuthbertson, D. J. (2026). Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD. Liver International, 46(4). https://doi.org/10.1111/liv.70562
Vancouver
Henney AE, Wilson J, Riley DR, Alam U, Cuthbertson DJ. Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD. Liver International. 2026;46(4). doi:10.1111/liv.70562
BibTeX
@article{Henney2026,
author = {Henney, Alex E and Wilson, Jo and Riley, David R and Alam, Uazman and Cuthbertson, Daniel J},
title = {Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD},
journal = {Liver International},
year = {2026},
volume = {46},
number = {4},
doi = {10.1111/liv.70562}
}
EUVIMED